knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 20:16:35 - browse：73

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Pfizer is about to make a big push in cancer. Will investors listen?

entertainment

WSS

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

What do new weight loss drugs mean for bariatric surgery?

CDC advisory group OKs chikungunya vaccine

CDC advisory group OKs chikungunya vaccine

Medicare isn't yet testing food as medicine

NEJM study measures Covid brain fog, impact on IQ

explore

knowledge

explore

Supreme Court strikes down use of affirmative action

How to make Best Hospitals ratings actually useful for patients

Trump demands the U.S. pay no more for drugs than other countries … again

Winners, losers from Medicare’s list of drugs subject to price talks

New air purifier tech could be key to improving indoor air quality

As pharma fights Medicare drug negotiation, hospitals, docs silent

Hepatitis C has a cure — but many Americans still lack access to it

As pharma fights Medicare drug negotiation, hospitals, docs silent

How one medical school became remarkably diverse

AstraZeneca challenges Medicare drug negotiation program

entertainment

Neuroscience renaissance leads to new crop of psychiatric drugs

Diversity in medical illustrations gets boost from Chidiebere Ibe

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Medicare Advantage isn’t working — for anyone

5 ways to address the shortage of health care workers

Using force crossed my mind when examining a defiant young patient

focus

knowledge

entertainment

hotspot